Supernus Pharmaceuticals (SUPN) - Cash per Share

The change in cash per share on this GURU.Markets chart, where the latest reading is 2.44, correlates with efficient inventory management and supply chain stability. The Supernus Pharmaceuticals (SUPN) strategy relies on organic R&D and the targeted licensing of new molecules. Deep expertise in developing extended-release medications for the treatment of epilepsy and ADHD serves as the foundation for success.
Comprehensive metric breakdowns and analytics for Supernus Pharmaceuticals, Inc. (SUPN)

The selection of defensive assets is based on an analysis of liquid reserves, which in the case of Supernus Pharmaceuticals (SUPN) provides funding for aggressive R&D and the acquisition of neurology biotech startups. This metric is calculated by dividing total cash holdings by the number of shares, and the trend of highly liquid assets per share allows an investor to assess the business's real margin of safety, eliminating the risk of hidden capital degradation.